Abstract: Objective:To observe the effect of atorvastatin on creactive protein (CRP),monocyte chemoattractant protein-1 (MCP-1) and urinary albumin excretion rate (UAER) in patients with diabetic nephropathy (DN).Methods:One hundred and eight DN patients were randomly divided into treatment group (54 cases) and atorvastatin group (54 cases).The treatment group were administered the routine therapy and the atorvastatin group received atorvastatin 40 mg daily.The therapies lasted for 12 weeks in both groups.Twenty healthy people acted as control.Serum CRP,MCP-1,glucose,lipids levels and UAER were compared between the two groups before treatment and 4,8,12 weeks after treatment.Results:Levels of plasma CRP,MCP-1 and UAER had no obvious difference between the two groups before treatment (P>0.05),but the above levels decreased significant in atorvastatin group after the therapy (P<0.01).Serum CRP,MCP-1 and UAER presented a positive correlation (P<0.01).Conclusions:Atorvastatin could effectively decrease the urinary protein excretion by restraining inflammation in DN patients.